Physician

Khizer Salim Shaikh, M.D.

According to 2025 Medicare claims, Khizer Shaikh, M.D. (NPI: 1255560884) practices pulmonary disease in the Lake Havasu City-Kingman, AZ market, with the plurality of this provider's patient population coming from Mohave, AZ. This provider's primary affiliated billing organization is HRMC, LLC (NPI: 1447630538; TIN: 753143244) and primary practice location at 86403-5607.

Shaikh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 568 traditional Medicare patients, billed 2,982 HCPCS/CPT codes, and received $355,470 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 1,797 prescription claims across 267 beneficiaries totaling $543,492 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 619 claims. Open Payments data shows 21 records totaling $562. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $65,054 to $355,470. Similarly, Part D prescription costs have risen steadily, from $29,806 to $543,492. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,663 and ending at $57,557.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	180	569	$65,054
2016	497	1,834	$198,261
2017	566	2,326	$264,743
2018	426	1,362	$148,123
2019	253	950	$114,047
2020	546	3,379	$421,333
2021	505	2,835	$356,469
2022	516	2,982	$367,287
2023	566	2,859	$325,078
2024	568	2,982	$355,470

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	68	216	$29,806
2016	195	1,093	$241,236
2017	244	1,671	$432,186
2018	204	1,314	$404,638
2019	115	328	$100,212
2020	190	1,058	$411,672
2021	198	1,008	$514,067
2022	223	1,269	$467,055
2023	212	1,374	$423,724
2024	267	1,797	$543,492

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$3,685
2016	163	839	$39,727
2017	381	1,554	$67,103
2018	426	1,861	$73,489
2019	191	801	$43,263
2020	195	937	$68,016
2021	136	924	$91,527
2022	120	802	$74,193
2023	113	841	$65,646
2024	90	619	$71,759

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	353	1,399	$166
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	182	367	$88
99292	Critical care, each additional 30 minutes	195	634	$84
76937	Ultrasonic guidance for blood vessel access	66	73	$11
94060	Test to measure expiratory airflow and volume changes before and after medication administration	111	112	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	137	9,030	$186,694
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	77	3,990	$82,078
Eliquis	Apixaban	53	2,220	$41,587
Breo Ellipta	Fluticasone/Vilanterol	32	2,100	$25,940
Spiriva Respimat	Tiotropium Bromide	15	1,170	$19,463

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	18	$18,151
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	Y	N/R	16	$16,206
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	22	173	$12,920
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	14	$12,105
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	16	$2,393

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$562	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Khizer Salim Shaikh, M.D.?

Tedicare shows public-source Medicare data for Khizer Salim Shaikh, M.D. (NPI 1255560884), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Khizer Salim Shaikh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Khizer Salim Shaikh, M.D.?

Khizer Salim Shaikh, M.D. is linked to HRMC, LLC (billing NPI 1447630538) in the available physician profile data.

Does Khizer Salim Shaikh, M.D. have Open Payments data?

Khizer Salim Shaikh, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.